

## **LISTING OF THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-24 (Canceled).

25. (Previously Presented) A crystalline form 1 of bilastine having, upon X-ray crystallography analysis, crystal parameters of substantially the following:

Crystallographic system	Monoclinic
Spatial group	P2 (1)/c
Crystal size	0.56 x 0.45 x 0.24 mm
Cell dimension	$a=23.38 (5)$ Å $\alpha = 90^\circ$
	$b=8.829 (17)$ Å $\beta = 90^\circ$
	$c=12.59 (2)$ Å $\gamma = 90^\circ$
Volume	$2600 \text{ \AA}^3$
Z, calculated density	4, $1.184 \text{ mg/m}^3$

, an infrared spectrum in potassium bromide with the following bands:

Wavenumber ( $\text{cm}^{-1}$ )

3057

2929

2883

2857

2797

1666

1481

1431

1346

1326

1288

1020

973

945

829

and an infrared spectrum in potassium bromide which is substantially identical to that shown in Figure 1.

Claims 26-32 (Canceled).

33. (Currently Amended) A process for preparing the crystalline form 1 of bilastine according to claim 25, wherein said process comprises:

- a) combining heating bilastine with [[in]] a solvent selected from the group consisting of isopropyllic alcohol, n-butanol and acetone to form a mixture and heating the mixture to a reflux temperature of said solvent[.] ;
- b) letting the mixture cool to room temperature;
- c) filtering off solid residue from said cooled mixture; and
- d) drying said solid residue to a constant weight.

34. (Currently Amended) A process for preparing the crystalline form 1 of bilastine according to claim 25, wherein said process comprises:

- a) combining heating crystalline form 2 of bilastine, or crystalline form 3 of bilastine, or a mixture thereof with [[in]] a solvent selected from the group consisting of isopropyllic alcohol, n-butanol and acetone to form a mixture and heating the bilastine/solvent mixture to a reflux temperature of the solvent[.] ;
- b) letting the mixture cool to room temperature;
- c) filtering off solid residue from said cooled mixture; and
- d) drying said solid residue to a constant weight.

35. (Currently Amended) A[[n]] solid antihistiminic pharmaceutical composition comprising the crystalline form 1 of bilastine according to claim 25 as an active ingredient together with at least one excipient.
36. (Previously Presented) A process for treating allergic diseases in a patient in need thereof, wherein the process comprises administering to said patient a pharmaceutical composition according to claim 35.
37. (Previously Presented) A process for treating allergic diseases in a patient in need thereof, wherein the process comprises administering to said patient an effective amount of crystalline form 1 of bilastine according to claim 25.